National Multiple Sclerosis Society News
-
The introduction of Biogen Idec Inc.’s multiple sclerosis pill, Tecfidera, outstripped the initial sales of competing drugs from Novartis AG and Sanofi, suggesting the treatment may beat estimates for the year.
-
Biogen Idec Inc., the fourth- largest U.S. biotechnology company by market value, rose to a record price after the drugmaker won U.S. approval for its first pill for multiple sclerosis, Tecfidera.
-
Biogen Idec Inc., the fourth- largest U.S. biotechnology company by market value, rose to a record price after the drugmaker won U.S. approval for its first pill for multiple sclerosis, Tecfidera.
-
Biogen Idec Inc., the fourth- largest U.S. biotechnology company by market value, won a U.S. patent that may guard its experimental multiple sclerosis pill from generic competition for eight more years than anticipated.
-
Biogen Idec Inc. won European Union backing for Tecfidera, one of the first therapies for multiple sclerosis available in an easy-to-take pill that analysts say may generate $3.25 billion in annual sales.
-
Sanofi won backing from a European advisory panel for its first multiple sclerosis therapy, the tablet Aubagio, a step forward in the French drugmaker’s plan to grab a slice of the $14 billion MS business.
-
Researchers identified a possible culprit for immune cells’ resistance to regulation in a small study of multiple sclerosis patients, suggesting a potential new target for treatment.
-
Biogen Idec Inc., the fourth- largest U.S. biotechnology company by market value, won a U.S. patent that may guard its experimental multiple sclerosis pill from generic competition for eight more years than anticipated.
-
Carol Patterson was waiting for a call from her doctor. When the phone rang on that afternoon in August 2011 at her home in Cortland, Ohio, it wasn’t a physician on the other end. A woman named Robin said she was representing the American Diabetes Association.
-
A cellular signature seen in the blood of multiple sclerosis patients may help determine their likelihood of relapse, potentially influencing which therapy physicians prescribe, a study found.
|
|
National Multiple Sclerosis Society Photos
Most Popular on Bloomberg
|
| |
Rate this Page